



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > Insulin aspart + niacinamide > Printer-friendly PDF

Insulin aspart + niacinamide

Trade Name:

Fiasp

Manufacturer/Distributor:

Novo Nordisk Canada

www.novonordisk.ca

1-800-465-4334

Classification:

Insulin analogue

ATC Class:

A10AB - insulin analogues for injection, fast-acting

Status:

active

Notice of Compliance (yyyy/mm/dd):

2017/02/02

Date Marketed in Canada (yyyy/mm/dd):

2017/04/06

Presentation:

Injection: 100 IU/mL. DIN: 02460408 - 10 mL vial

Injection: 100 IU/mL. DIN: 02460416 - 3 mL penfill cartridge

Injection: 100 IU/mL. DIN: 02460424 - 3 mL pre-filled pwn

Comments:

Fiasp contains insulin aspart as well as niacinamide (vitamin B3) which results in a faster initial absorption of insulin, leading to an earlier onset and greater early insulin exposure. The onset of action is about five minutes earlier with Fiasp than with NovoRapid (insulin aspart) and the peak effect occurs approximately 11 minutes earlier. Therefore, if hypoglycemia occurs, it may occur earlier after an injection of Fiasp compared with other mealtime insulins.

Source:

Canadian Healthcare Network 06 April 2017

Keywords: insulin aspart

diabetes mellitus: insulin dependent

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the [Health Canada Drug Product Database](#)

Status:**Search Terms:**

[A \(37\)](#) | [B \(20\)](#) | [C \(24\)](#) | [D \(37\)](#) | [E \(40\)](#) | [F \(12\)](#) | [G \(11\)](#) | [H \(9\)](#) | [I \(24\)](#) | [K \(1\)](#) | [L \(26\)](#) | [M \(12\)](#) | [N \(7\)](#) | [O \(12\)](#) | [P \(28\)](#) | [R \(14\)](#) | [S \(27\)](#) | [T \(33\)](#) | [U \(4\)](#) | [V \(13\)](#) | [W \(2\)](#) | [Z \(4\)](#)

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Abatacept</u>	Orencia	Co-stimulation modulator for rheumatoid arthritis	2006/09
<u>Abemaciclib</u>	Verzenio	Protein kinase inhibitor	2019/07/03
<u>Abiraterone</u>	Zytiga	Androgen biosynthesis inhibitor	2011/08/08
<u>Acamprosate</u>	Campral	Alcohol abstinence aid	2007/03
<u>Acclidinium + formoterol</u>	Duaklir Genuair	Bronchodilator combination - LAMA plus LABA	2015/07/09
<u>Acclidinium bromide</u>	Tudorza Genuair	Bronchodilator	2013-09
<u>Adapalene + benzoyl peroxide</u>	Tactuo	Acne therapy	2011/04
<u>Adefovir dipivoxil</u>	Hepsera	Antiviral agent	2006/10
<u>Afatinib</u>	Giotrif	Protein kinase inhibitor	2014/05/28
<u>Albiglutide</u>	Eperzan	Antihyperglycemic agent	2016/02/19
<u>Alendronate</u>	Fosamax	Bone resorption inhibitor	2011/03
<u>Alglucosidase alfa</u>	Myozyme	Enzyme replacement therapy	2007/04
<u>Aliskiren and hydrochlorothiazide</u>	Rasilez HCT	Renin inhibitor and diuretic	2009/09
<u>Alitretinoin</u>	Toctino	Immunomodulator, antiinflammatory agent	2010/10/19
<u>Alogliptin</u>	Nesina	Oral antihyperglycemic agent	2014/10/08
<u>Alogliptin + metformin</u>	Kazano	Oral antihyperglycemic agent	2014/10/08
<u>Alpelisib</u>	Piqray	Antineoplastic agent	2020/03/11

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Aluminum chloride hexahydrate</u>	Hydrosal gel	Antiperspirant	
<u>Aminophylline</u>	Phyllocontin	Bronchodilator	2010
<u>Apalutamide</u>	Erleada	Anti-androgen	2018/07/27
<u>Apixaban</u>	Eliquis	Anticoagulant	2012/03
<u>Apomorphine</u>	Movapo	Nonergot-derivative dopamine receptor agonist	2018/04/xx
<u>Apomorphine</u>	Kynmobi	Nonergot-derivative dopamine receptor agonist	2020/06/12
<u>Apremilast</u>	Otezla	Immunosuppressant agent	2014/12/08
<u>Aripiprazole</u>	Abilify	Antipsychotic agent	2009/07/03
<u>ASA + Meprobamate + Codeine + Caffeine</u>	282 MEP	Narcotic analgesic	
<u>Asenapine</u>	Saphris	Atypical antipsychotic	2012/03/16
<u>Asunaprevir</u>	Sunvepra	Antiviral agent	2016/04/22
<u>Avelumab</u>	Bavencio	Antineoplastic agent	2017/12/18
<u>Axicabtagene ciloleucel</u>	Yescarta	Antineoplastic agent	2019/11/27
<u>Axitinib</u>	Inlyta	Anti-tumor agent	2012/09
<u>Azacitidine</u>	Vidaza	Antineoplastic agent	2009/12/07
<u>Azelastine + fluticasone</u>	Dymista	Antihistamine and corticosteroid agent	2015/10/22
<u>Azilsartan</u>	Edarbi	Antihypertensive agent	2013/03/27
<u>Azilsartan + chlorthalidone</u>	Edarbyclor	Antihypertensive agent	2013/03/27
<u>Azithromycin dihydrate</u>	Zmax SR	Antibiotic	2010/10/29

1 2 3 4 5 6 7 8 9 ? next ? last »

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the x?m??k??y??m (Musqueam), Sk?wx?wu?mesh U?xwumixw (Squamish Nation), and s?l?ilw?ta? (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2025-06-03 09:24): <http://www.dpic.org/druglisting/insulin-aspart-niacinamide>